Axcelis Technologies delivered a Q2 FY2026 print on August 6, 2026 that did two things at once: it confirmed that the company's mature-process ion implant franchise has stabilized after the FY2024-FY2025 downcycle, and it re-anchored the equity narrative on a pending all-stock merger with Veeco Instruments that remains the load-bearing event for the rest of 2026. Q2 revenue of $215.2 million was up 10.6% year over year, GAAP gross margin of 42.4% held inside the 42-to-45% range the company has run for the last six quarters, and adjusted EBITDA of $36.0 million (16.7% margin) was modestly below the prior-year $38.9 million because general and administrative expense spiked 37% to $22.4 million on Veeco-related professional fees that totaled $4.8 million in the quarter and $15.2 million in the first half. The investment question is no longer whether Axcelis can grow through the China export-control overhang, because it can; the question is whether the market is correctly pricing the merger close and the combined-company cost synergies in the run-up to the China SAMR antitrust decision, which is the last major regulatory clearance the deal needs. The shares closed at $140.15 on August 14, 2026, valuing Axcelis at roughly $4.33 billion on 30.88 million diluted shares, and the Veeco fixed exchange ratio of 0.3575 implies 21.85 million new Axcelis shares issued at the close for a pro-forma share count of approximately 52.7 million, or 41% dilution to existing holders, in exchange for a $3.2 billion-revenue semiconductor process-equipment peer that is itself levered to the same customer set. The next data point that tests the thesis is the China SAMR decision, which both companies state they expect in the second half of 2026, followed by the Q3 FY2026 print (revenue guided to approximately $230 million) which is the first quarter that should show the SiC power-device and DRAM mix-shift in operating leverage if the management thesis is correct.